CollPlant Biotechnologies Ltd. Sponsored ADR (NASDAQ:CLGN) Short Interest Up 498.5% in August

CollPlant Biotechnologies Ltd. Sponsored ADR (NASDAQ:CLGN) was the recipient of a significant growth in short interest in the month of August. As of August 31st, there was short interest totaling 131,118 shares, a growth of 498.5% from the August 15th total of 21,907 shares. Based on an average daily volume of 17,402,039 shares, the short-interest ratio is presently 0.0 days. Approximately 10.0% of the shares of the stock are sold short.

CollPlant Biotechnologies Stock Performance

CLGN stock traded down $0.04 during midday trading on Friday, hitting $3.50. 126,895 shares of the stock were exchanged, compared to its average volume of 1,043,771. The stock’s 50-day moving average price is $3.32 and its 200-day moving average price is $4.09. The stock has a market cap of $5.05 million, a price-to-earnings ratio of -0.24 and a beta of 1.79. CollPlant Biotechnologies has a fifty-two week low of $2.64 and a fifty-two week high of $31.80.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of CollPlant Biotechnologies in a research report on Friday, September 4th. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Reduce” and a consensus target price of $120.00.

Institutional Investors Weigh In On CollPlant Biotechnologies

An institutional investor recently raised its position in CollPlant Biotechnologies stock. Pinnacle Associates Ltd. boosted its holdings in CollPlant Biotechnologies Ltd. Sponsored ADR (NASDAQ:CLGN) by 9.9% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 557,193 shares of the company’s stock after acquiring an additional 50,000 shares during the period. Pinnacle Associates Ltd. owned 4.36% of CollPlant Biotechnologies worth $780,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 21.69% of the company’s stock.

About CollPlant Biotechnologies

CollPlant Biotechnologies Ltd. (NASDAQ: CLGN) is a regenerative medicine company that develops and commercializes recombinant human collagen (rhCollagen) and 3D bioprinting technologies for medical and aesthetic applications. The company’s proprietary plant-based rhCollagen is produced using genetically engineered tobacco plants to provide a scalable, animal-free source of human collagen that meets regulatory standards.

CollPlant’s product portfolio includes Vergenix™ wound care matrices and dermal fillers for aesthetic and reconstructive purposes, as well as a range of bioinks designed for 3D bioprinting of soft and hard tissues.